Kimberly Gentile
Chief Tech/Sci/R&D Officer chez BIOHAVEN LTD.
Fortune : 5 M $ au 31/03/2024
Profil
Mme Kimberly Gentile est vice-présidente principale des opérations cliniques chez Biohaven Pharmaceutical Holding Co. Ltd. et directrice des opérations chez Portage Pharmaceutical Ltd. Mme Gentile était auparavant employée en tant que directrice associée chez Bristol Myers Squibb Co. et en tant que Senior Manager-Clinical Trail chez SCIREX Corp. Elle a obtenu son diplôme de premier cycle à la Salem State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOHAVEN LTD.
0,12% | 04/03/2024 | 95 969 ( 0,12% ) | 5 M $ | 31/03/2024 |
Postes actifs de Kimberly Gentile
| Sociétés | Poste | Début |
|---|---|---|
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - |
Portage Pharmaceutical Ltd.
 Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Chief Operating Officer | - |
Anciens postes connus de Kimberly Gentile
| Sociétés | Poste | Fin |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 03/10/2022 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/02/2014 |
| SCIREX Corp. | Corporate Officer/Principal | 01/06/2000 |
Formation de Kimberly Gentile
| Salem State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| SCIREX Corp. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Commercial Services |
